Lymphoma encompasses a variety of blood cancers of the lymphatic system. Non-Hodgkin’s Lymphoma (NHL) for example, is diagnosed in over 100,000 every year in the US and EU combined. An array of expert reports in our Lymphoma Section enable you to investigate drug development strategies and market trends for NHL, Hodgkin’s Lymphoma, Skin Lymphoma, T-Cell Lymphoma, Indolent Lymphoma and other variants. Investigate key issues such as licensing, R&D, industry alliances, generic drugs (rituximab,
bortezomib, doxorubicin, bleomycin, vinblastine, etc.) and the activities of major pharmaceutical players such as Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis.